-
Subject Areas on Research
-
"Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.
-
A Double-Blinded, Randomized, Placebo-Controlled Trial to Evaluate Efficacy, Safety, and Tolerability of Single Doses of Tirasemtiv in Patients with Acetylcholine Receptor-Binding Antibody-Positive Myasthenia Gravis.
-
A Phase I study of arsenic trioxide (Trisenox), ascorbic acid, and bortezomib (Velcade) combination therapy in patients with relapsed/refractory multiple myeloma.
-
A clinician's view of voxelotor.
-
A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial.
-
A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer.
-
Activation by odorants of a multistate cation channel from olfactory cilia.
-
Activation of NAD(P)H oxidase by lipid hydroperoxides: mechanism of oxidant-mediated smooth muscle cytotoxicity.
-
Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells.
-
Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease.
-
Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells.
-
Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis.
-
Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study.
-
Coordinated cerebellar climbing fiber activity signals learned sensorimotor predictions.
-
Cyclin D1 overexpression and response to bortezomib treatment in a breast cancer model.
-
Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma.
-
Effect of Cisplatin and Gemcitabine With or Without Berzosertib in Patients With Advanced Urothelial Carcinoma: A Phase 2 Randomized Clinical Trial.
-
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.
-
Effect of amiloride and some of its analogues of cation transport in isolated frog skin and thin lipid membranes.
-
Effects of checkpoint kinase 1 inhibition by prexasertib on the tumor immune microenvironment of head and neck squamous cell carcinoma.
-
Effects of chemical group specific reagents on sodium entry and the amiloride binding site in frog skin: evidence for separate sites.
-
Evidence-Based Guidelines Should Be Used To Inform COVID-19 Management.
-
Experience in Transitioning From Parenteral Prostacyclins to Selexipag in Pulmonary Arterial Hypertension.
-
Function of nuclear factor kappaB in pancreatic cancer metastasis.
-
Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML.
-
Glucocorticoid receptor triggers a reversible drug-tolerant dormancy state with acquired therapeutic vulnerabilities in lung cancer.
-
Gut hormone pharmacology of a novel GPR119 agonist (GSK1292263), metformin, and sitagliptin in type 2 diabetes mellitus: results from two randomized studies.
-
Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program.
-
Multiple myeloma, version 1.2013.
-
Neihumicin, a new cytotoxic antibiotic from Micromonospora neihuensis. II. Structural determination and total synthesis.
-
New combination treatments in the management of diabetes: focus on sitagliptin-metformin.
-
Novel role for endogenous hepatocyte growth factor in the pathogenesis of intracranial aneurysms.
-
Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells.
-
Outcomes of autologous hematopoietic cell transplantation in primary amyloidosis after bortezomib-based induction therapy.
-
PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma.
-
Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207.
-
Phase II trial of intravenous CI-980 (NSC 370147) in patients with metastatic colorectal carcinoma. Model for prospective evaluation of neurotoxicity.
-
Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma.
-
Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
-
Proteasome inhibitor attenuates skeletal muscle reperfusion injury by blocking the pathway of nuclear factor-kappaB activation.
-
Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer.
-
Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer.
-
Randomized phase II trial of docetaxel plus cetuximab or docetaxel plus bortezomib in patients with advanced non-small-cell lung cancer and a performance status of 2: CALGB 30402.
-
Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease.
-
Real-world effectiveness of voxelotor for treating sickle cell disease in the US: a large claims data analysis.
-
Response and resistance to NF-κB inhibitors in mouse models of lung adenocarcinoma.
-
SYK inhibitor entospletinib prevents ocular and skin GVHD in mice.
-
Safety and efficacy of weekly oral oltipraz in chronic smokers.
-
Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study.
-
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.
-
Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206.
-
Stabilization of p53 is a novel mechanism for proapoptotic function of NF-kappaB.
-
Synergistic effects of nelfinavir and bortezomib on proteotoxic death of NSCLC and multiple myeloma cells.
-
TRPV4 channel opening mediates pressure-induced pancreatitis initiated by Piezo1 activation.
-
Targeting Dormant Ovarian Cancer Cells In Vitro and in an In Vivo Mouse Model of Platinum Resistance.
-
The function of multiple IkappaB : NF-kappaB complexes in the resistance of cancer cells to Taxol-induced apoptosis.
-
The incretins and beta-cell health: contrasting glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 as a path to understand islet function in diabetes.
-
What should work, may not.